🔍 Observations
Topline
- Revenue from operations grew 15.8% YoY (₹217,940 Mn → ₹252,285 Mn), with all three core segments contributing — Healthcare Services (+13.6%), Retail Health & Diagnostics (+20.1%), and Digital Health & Pharmacy (+18.9%).
- Q4FY26 revenue at ₹66,055 Mn grew 18.1% YoY over Q4FY25 (₹55,922 Mn), maintaining strong sequential momentum.
- Digital Health & Pharmacy is now 43% of consolidated revenues, cementing its role as the volume engine.
Bottomline
- PAT grew 33.1% YoY (₹15,051 Mn → ₹20,027 Mn), significantly outpacing revenue growth — a clear sign of operating leverage kicking in.
- Basic EPS jumped from ₹100.56 to ₹135.04 (+34.3% YoY), reflecting earnings accretion without dilution.
- Q4FY26 PAT of ₹5,513 Mn grew 33% YoY over Q4FY25 (₹4,145 Mn), sustaining the annual acceleration trend.
Margins
- EBITDA proxy (PBT + Finance costs + D&A): FY26 = ₹26,609 + ₹4,496 + ₹8,761 = ₹39,866 Mn on revenues of ₹252,285 Mn → EBITDA margin ~15.8% vs FY25 (₹20,391 + ₹4,585 + ₹7,575 = ₹32,551 Mn on ₹217,940 Mn) → ~14.9%. Margin expanded ~90 bps YoY.
- Net profit margin: FY26 = 7.9% vs FY25 = 6.9% — 100 bps expansion, driven by Digital Health segment swinging to meaningful profitability (₹1,127 Mn → ₹3,987 Mn segment result).
- Retail Health & Diagnostics segment result nearly tripled (₹300 Mn → ₹723 Mn), adding further margin uplift.
Growth Trajectory
- Three-year compounding is clearly accelerating: PAT grew 33% this year versus revenue growth of 16% — bottomline is finally outrunning topline.
- Digital Health segment results surged 254% YoY (₹1,127 Mn → ₹3,987 Mn), signalling a structural shift from investment phase to profit contribution.
- Segment result margin for Healthcare Services: FY26 = 24,303/127,501 = 19.1% vs FY25 = 21,295/112,201 = 19.0% — core hospital margins holding steady while adjacencies scale.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- PAT growing 2x the pace of revenue confirms operating leverage is real and compounding — margin expansion is structural, not a one-off.
- Digital Health segment profit up 254% YoY (₹1,127 Mn → ₹3,987 Mn) — the highest-volume segment is now earnings-accretive, removing a longstanding drag.
- Operating cash flow surged 33.7% YoY (₹21,364 Mn → ₹28,557 Mn) — earnings quality is high; profit growth is translating to cash.
- Long-term debt reduced sharply (₹44,170 Mn → ₹24,301 Mn) — significant deleveraging of non-current borrowings signals balance sheet discipline.
- Retail Health & Diagnostics nearly tripled segment profit (₹300 Mn → ₹723 Mn) — a third profit engine is now meaningfully contributing.
- EPS up 34.3% YoY with zero dilution — capital allocation is shareholder-friendly.
- Free cash flow positive: Operating cash flow ₹28,557 Mn minus capex ₹19,620 Mn = FCF of ~₹8,937 Mn — company is self-funding growth.
🔴 Red Flags
- Current borrowings spiked from ₹8,582 Mn to ₹32,284 Mn — a near 4x jump in short-term debt warrants scrutiny on refinancing risk, even as long-term debt declined.
- Trade receivables up 15.5% (₹30,161 Mn → ₹34,849 Mn), growing in line with revenue — collection efficiency needs monitoring as Digital Health scales.
- Capex intensity remains high at ₹19,620 Mn (vs ₹17,127 Mn in FY25) — growth is capex-heavy; returns on deployed capital will take time to materialise.
- Subsidiary acquisition spend of ₹13,003 Mn in FY26 investing outflows (vs ₹24 Mn in FY25) — significant inorganic outflow reduces cash visibility; nature and returns profile of acquired entity not disclosed in this data.
- Other expenses grew 17% YoY (₹46,030 Mn → ₹53,833 Mn), slightly ahead of revenue — requires watching if scale benefits don’t materialise.
- Other financial liabilities (current) fell sharply from ₹8,598 Mn to ₹3,310 Mn while current borrowings surged — liability reclassification dynamics need closer reading in full notes.
📊 Balance Sheet Analysis
- Equity base strengthened: Total equity grew from ₹86,529 Mn to ₹99,745 Mn (+15.3%), driven by retained earnings; book value per share rising steadily.
- Leverage picture mixed: Gross debt (non-current + current borrowings) = ₹56,585 Mn vs FY25 ₹52,752 Mn — marginally higher; but the shift toward short-term debt (₹32,284 Mn) from long-term is the structural concern despite headline long-term reduction.
- Asset quality sound: Goodwill stable at ₹10,323 Mn; PPE growing purposefully with capex; CWIP at ₹9,915 Mn signals capacity being added.
- Net debt: Gross borrowings ₹56,585 Mn minus cash + liquid investments (₹8,113 Mn + ₹10,165 Mn + ₹3,055 Mn) = ~₹35,252 Mn — manageable relative to EBITDA of ~₹39,866 Mn (net debt/EBITDA ~0.9x).
💰 Cash Flow Analysis
- Operating cash flow of ₹28,557 Mn (up 33.7% YoY) is the headline — conversion of profit to cash is high quality, with D&A and working capital the primary adds.
- Working capital consumed ₹5,700 Mn (net of receivables, payables, inventory) — receivables growth is the main drag; inventory and payables roughly neutral.
- Investing outflows of ₹21,482 Mn absorbed by capex (₹19,620 Mn) and subsidiary acquisition (₹13,003 Mn), partially offset by current investment redemptions (net ~₹5,000 Mn proceeds).
- Financing saw net debt addition (₹11,149 Mn raised, ₹7,340 Mn repaid), with dividends of ₹2,876 Mn paid — free cash flow after dividends approximately ₹6,061 Mn, confirming self-sustaining growth model.
💡 Investment Outlook
Apollo Hospitals is at a genuine earnings inflection: PAT growing 33% on 16% revenue growth, with Digital Health crossing into meaningful profitability after years of investment — this is precisely the margin expansion re-rating catalyst that compresses EV/EBITDA multiples.
The balance sheet is broadly sound (net debt/EBITDA ~0.9x), though the sharp spike in current borrowings and a large opaque subsidiary acquisition deserve close scrutiny in the detailed annual report.
FCF generation of ~₹8,937 Mn confirms the business is self-funding at scale.
If Digital Health and Retail Diagnostics sustain their profit trajectory, consensus earnings upgrades are likely — but near-term debt structure and capex intensity remain the key monitoring variables.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.